

Jos Prickaerts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/262319/publications.pdf>

Version: 2024-02-01

74
papers

2,942
citations

201674

27
h-index

182427

51
g-index

79
all docs

79
docs citations

79
times ranked

3656
citing authors

#	ARTICLE	IF	CITATIONS
1	The sGC stimulator BAY-747 and activator runcaciguat can enhance memory in vivo via differential hippocampal plasticity mechanisms. <i>Scientific Reports</i> , 2022, 12, 3589.	3.3	5
2	Biased 5-HT1A receptor agonists F13714 and NLX-101 differentially affect pattern separation and neuronal plasticity in rats after acute and chronic treatment. <i>Molecular and Cellular Neurosciences</i> , 2022, 120, 103719.	2.2	3
3	Inhibition of PDE2 and PDE4 synergistically improves memory consolidation processes. <i>Neuropharmacology</i> , 2021, 184, 108414.	4.1	9
4	Increased isoform-specific phosphodiesterase 4D expression is associated with pathology and cognitive impairment in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 97, 56-64.	3.1	15
5	The 5-HT1A receptor as a serotonergic target for neuroprotection in cerebral ischemia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110210.	4.8	9
6	Roflumilast protects against spatial memory impairments and exerts anti-inflammatory effects after transient global cerebral ischemia. <i>European Journal of Neuroscience</i> , 2021, 53, 1171-1188.	2.6	11
7	Pharmacological inhibition of phosphodiesterase 7 enhances consolidation processes of spatial memory. <i>Neurobiology of Learning and Memory</i> , 2021, 177, 107357.	1.9	8
8	PDE inhibition in distinct cell types to reclaim the balance of synaptic plasticity. <i>Theranostics</i> , 2021, 11, 2080-2097.	10.0	13
9	Protein kinase G phosphorylates the Alzheimer's disease-associated tau protein at distinct Ser/Thr sites. <i>BioFactors</i> , 2021, 47, 126-134.	5.4	5
10	The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors. <i>Pharmacological Reviews</i> , 2021, 73, 1016-1049.	16.0	33
11	Positive effects of roflumilast on behavior, neuroinflammation, and white matter injury in mice with global cerebral ischemia. <i>Behavioural Pharmacology</i> , 2021, 32, 459-471.	1.7	6
12	Andrographolide blocks 50-kHz ultrasonic vocalizations, hyperlocomotion and oxidative stress in an animal model of mania. <i>Journal of Psychiatric Research</i> , 2021, 139, 91-98.	3.1	5
13	Facilitation of TRKB Activation by the Angiotensin II Receptor Type-2 (AT2R) Agonist C21. <i>Pharmaceuticals</i> , 2021, 14, 773.	3.8	3
14	Soluble Guanylate Cyclase Stimulator Vericiguat Enhances Long-Term Memory in Rats without Altering Cerebral Blood Volume. <i>Biomedicines</i> , 2021, 9, 1047.	3.2	10
15	DNA methylation regulates the expression of the negative transcriptional regulators ID2 and ID4 during OPC differentiation. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 6631-6644.	5.4	20
16	Pro-cognitive effect of upregulating cyclic guanosine monophosphate signalling during memory acquisition or early consolidation is mediated by increased AMPA receptor trafficking. <i>Journal of Psychopharmacology</i> , 2020, 34, 103-114.	4.0	12
17	Activation of 5-HT1A postsynaptic receptors by NLX-101 results in functional recovery and an increase in neuroplasticity in mice with brain ischemia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109832.	4.8	26
18	Sphingosine-1-Phosphate Receptor Modulators and Oligodendroglial Cells: Beyond Immunomodulation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7537.	4.1	23

#	ARTICLE	IF	CITATIONS
19	Pharmacological depletion of microglia and perivascular macrophages prevents vascular Cognitive Impairment in Ang II-induced Hypertension. <i>Theranostics</i> , 2020, 10, 9512-9527.	10.0	48
20	Persistence of the extinction of fear memory requires late-phase cAMP/PKA signaling in the infralimbic cortex. <i>Neurobiology of Learning and Memory</i> , 2020, 172, 107244.	1.9	14
21	Role of cyclic nucleotides and their downstream signaling cascades in memory function: Being at the right time at the right spot. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 113, 12-38.	6.1	36
22	Phosphodiesterase inhibitors roflumilast and vardenafil prevent sleep deprivation-induced deficits in spatial pattern separation. <i>Synapse</i> , 2020, 74, e22150.	1.2	9
23	Dietary plant stanol ester supplementation reduces peripheral symptoms in a mouse model of Niemann-Pick type C1 disease. <i>Journal of Lipid Research</i> , 2020, 61, 830-839.	4.2	5
24	Targeting Phosphodiesterases – Towards a Tailor-Made Approach in Multiple Sclerosis Treatment. <i>Frontiers in Immunology</i> , 2019, 10, 1727.	4.8	28
25	Phosphodiesterase Type 4 Inhibition in CNS Diseases. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 971-985.	8.7	41
26	From OPC to Oligodendrocyte: An Epigenetic Journey. <i>Cells</i> , 2019, 8, 1236.	4.1	74
27	Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study. <i>Neurobiology of Aging</i> , 2019, 77, 37-43.	3.1	43
28	Validation of the xylazine/ketamine anesthesia test as a predictor of the emetic potential of pharmacological compounds in rats. <i>Neuroscience Letters</i> , 2019, 699, 41-46.	2.1	15
29	Antagonizing $\alpha 7$ nicotinic receptors with methyllycaconitine (MLA) potentiates receptor activity and memory acquisition. <i>Cellular Signalling</i> , 2019, 62, 109338.	3.6	21
30	Effects of DNA methyltransferase inhibition on pattern separation performance in mice. <i>Neurobiology of Learning and Memory</i> , 2019, 159, 6-15.	1.9	5
31	Gestational stress in mouse dams negatively affects gestation and postpartum hippocampal BDNF and P11 protein levels. <i>Molecular and Cellular Neurosciences</i> , 2018, 88, 292-299.	2.2	9
32	Acute stress negatively affects object recognition early memory consolidation and memory retrieval unrelated to state-dependency. <i>Behavioural Brain Research</i> , 2018, 345, 9-12.	2.2	11
33	Acute administration of roflumilast enhances sensory gating in healthy young humans in a randomized trial. <i>Psychopharmacology</i> , 2018, 235, 301-308.	3.1	12
34	Roflumilast promotes memory recovery and attenuates white matter injury in aged rats subjected to chronic cerebral hypoperfusion. <i>Neuropharmacology</i> , 2018, 138, 360-370.	4.1	37
35	Assessing spatial pattern separation in rodents using the object pattern separation task. <i>Nature Protocols</i> , 2018, 13, 1763-1792.	12.0	20
36	Hypertension-induced cognitive impairment: insights from prolonged angiotensin II infusion in mice. <i>Hypertension Research</i> , 2018, 41, 817-827.	2.7	36

#	ARTICLE	IF	CITATIONS
37	The effects of the soluble guanylate cyclase stimulator riociguat on memory performance in healthy volunteers with a biperiden-induced memory impairment. <i>Psychopharmacology</i> , 2018, 235, 2407-2416.	3.1	10
38	Pneumococcal Immunization Reduces Neurological and Hepatic Symptoms in a Mouse Model for Niemann-Pick Type C1 Disease. <i>Frontiers in Immunology</i> , 2018, 9, 3089.	4.8	8
39	Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 46320.	3.3	63
40	Early postnatal iron deficiency impacts plasticity in the dorsal and ventral hippocampus in piglets. <i>International Journal of Developmental Neuroscience</i> , 2017, 59, 47-51.	1.6	11
41	From Age-Related Cognitive Decline to Alzheimer's Disease: A Translational Overview of the Potential Role for Phosphodiesterases. <i>Advances in Neurobiology</i> , 2017, 17, 135-168.	1.8	22
42	Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1033-1048.	4.1	128
43	The phosphodiesterase type 2 inhibitor BAY 607550 reverses functional impairments induced by brain ischemia by decreasing hippocampal neurodegeneration and enhancing hippocampal neuronal plasticity. <i>European Journal of Neuroscience</i> , 2017, 45, 510-520.	2.6	21
44	Physiological and pathological processes of synaptic plasticity and memory in drug discovery: Do not forget the dose-response curve. <i>European Journal of Pharmacology</i> , 2017, 817, 59-70.	3.5	6
45	Fluoxetine Treatment Induces Seizure Behavior and Premature Death in APPswe/PS1dE9 Mice. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 677-682.	2.6	13
46	Rolipram improves cognition, reduces anxiety- and despair-like behaviors and impacts hippocampal neuroplasticity after transient global cerebral ischemia. <i>Neuroscience</i> , 2016, 326, 69-83.	2.3	56
47	New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 82-102.	5.5	31
48	Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats. <i>Psychopharmacology</i> , 2016, 233, 3113-3124.	3.1	51
49	The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses. <i>Behavioural Brain Research</i> , 2016, 303, 26-33.	2.2	94
50	TrkB in the hippocampus and nucleus accumbens differentially modulates depression-like behavior in mice. <i>Behavioural Brain Research</i> , 2016, 296, 15-25.	2.2	22
51	Differential susceptibility to chronic social defeat stress relates to the number of Dnmt3a-immunoreactive neurons in the hippocampal dentate gyrus. <i>Psychoneuroendocrinology</i> , 2015, 51, 547-556.	2.7	27
52	The use of EEG parameters as predictors of drug effects on cognition. <i>European Journal of Pharmacology</i> , 2015, 759, 163-168.	3.5	14
53	Defeat stress in rodents: From behavior to molecules. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 59, 111-140.	6.1	185
54	Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction. <i>Current Pharmaceutical Design</i> , 2015, 21, 3813-3828.	1.9	30

#	ARTICLE	IF	CITATIONS
55	Purinergic Signaling and Hippocampal Long-Term Potentiation. <i>Current Neuropharmacology</i> , 2014, 12, 37-43.	2.9	25
56	Translational Issues with the Development of Cognition Enhancing Drugs. <i>Frontiers in Neurology</i> , 2014, 5, 190.	2.4	8
57	Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia. <i>Behavioural Brain Research</i> , 2014, 272, 248-251.	2.2	19
58	Improved Long-Term Memory via Enhancing cGMP-PKG Signaling Requires cAMP-PKA Signaling. <i>Neuropsychopharmacology</i> , 2014, 39, 2497-2505.	5.4	90
59	Long-term effects of prenatal allopurinol treatment on brain plasticity markers in low and normal birth weight piglets. <i>International Journal of Developmental Neuroscience</i> , 2014, 33, 29-32.	1.6	7
60	PDE4D inhibitors: A potential strategy for the treatment of memory impairment?. <i>Neuropharmacology</i> , 2014, 85, 290-292.	4.1	10
61	PDE5 Inhibition Improves Object Memory in Standard Housed Rats but Not in Rats Housed in an Enriched Environment: Implications for Memory Models?. <i>PLoS ONE</i> , 2014, 9, e111692.	2.5	10
62	Inhibition of phosphodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801. <i>Behavioural Brain Research</i> , 2013, 236, 16-22.	2.2	75
63	Object recognition testing: Statistical considerations. <i>Behavioural Brain Research</i> , 2012, 232, 317-322.	2.2	90
64	EVP-6124, a novel and selective $\alpha 7$ nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of $\alpha 7$ nicotinic acetylcholine receptors. <i>Neuropharmacology</i> , 2012, 62, 1099-1110.	4.1	194
65	Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: Indications for central and peripheral mechanisms. <i>Neurobiology of Learning and Memory</i> , 2012, 97, 370-379.	1.9	60
66	Object recognition testing: Methodological considerations on exploration and discrimination measures. <i>Behavioural Brain Research</i> , 2012, 232, 335-347.	2.2	160
67	Object recognition testing: Rodent species, strains, housing conditions, and estrous cycle. <i>Behavioural Brain Research</i> , 2012, 232, 323-334.	2.2	98
68	Differential BDNF Responses of Triple Versus Dual Reuptake Inhibition in Neuronal and Astrocytoma Cells as well as in Rat Hippocampus and Prefrontal Cortex. <i>Journal of Molecular Neuroscience</i> , 2012, 48, 167-175.	2.3	14
69	Liver X receptor activation restores memory in aged AD mice without reducing amyloid. <i>Neurobiology of Aging</i> , 2011, 32, 1262-1272.	3.1	118
70	Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: acquisition versus consolidation. <i>Psychopharmacology</i> , 2005, 177, 381-390.	3.1	120
71	Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. <i>Neurochemistry International</i> , 2004, 45, 915-928.	3.8	139
72	cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation. <i>European Journal of Pharmacology</i> , 2002, 436, 83-87.	3.5	120

#	ARTICLE	IF	CITATIONS
73	Local inhibition of hippocampal nitric oxide synthase does not impair place learning in the Morris water escape task in rats. <i>European Journal of Neuroscience</i> , 1999, 11, 223-232.	2.6	43
74	NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. <i>Oncotarget</i> , 0, 7, 41251-41264.	1.8	65